Best GLP-1 tablets and lozenges, ranked on care
Only sellers that price a GLP-1 you do not inject, each ranked on that product rather than on its injection, which is priced and studied differently.
Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
11 sellers are partners on this board today, sorted first and labeled Partner — the one respect in which the ordering is commercial. Every other seller here is ranked purely on the published rubric, which cannot see commercial status either way.
The board at a glance
- 50 sellers are on the GLP-1 tablet and lozenge board; 22 of them name their compounding pharmacy, and 5 require a consultation before any prescription.
- The lowest monthly figure published in this board's scope is $99/mo, for Semaglutide sublingual at Strut Health; price is 6% of the order here, so it does not decide the rank.
- 4 of the 50 price semaglutide and tirzepatide in both forms, so you can compare the two at one seller.
What the evidence says, before the sellers
- SemaglutideFDA-approved
Large trials for weight. 1 randomized trial of 1,000 or more people cited here for weight.
Every trial above used the approved product at labeled doses. None tested a compounded preparation, so their results describe Wegovy, not what a compounding pharmacy makes.
- TirzepatideFDA-approved
Large trials for weight. 1 randomized trial of 1,000 or more people cited here for weight.
Both trials used the approved product. Neither tested a compounded preparation, so the numbers describe Zepbound, not a pharmacy's version of it.
The ranking
Each seller below prescribes semaglutide or tirzepatide as a oral and a sublingual and has a full review on this site; compare the first six below, then expand another group for more providers.
These service details do not establish treatment effectiveness. Read the assessments below for the evidence, pharmacy information and published prices.
- Rank01
LttlPartner
Lttl is first on the GLP-1 tablet and lozenge board, carried by its follow-up mark and its price as the dose rises mark; its weakest mark here is stays within legal scope.
Lttl's own spread between forms: Semaglutide oral from $179 per 4 wks; $194 a calendar month, our arithmetic against injection from $149 per 4 wks; $161 a calendar month, our arithmetic and Semaglutide oral from $179 per 4 wks; $194 a calendar month, our arithmetic against injection from $99 per 4 wks; $107 a calendar month, our arithmetic.
- What it prices here
- Semaglutide oral (compounded)from $179 per 4 wks$194 a calendar month, our arithmetic
- Prescriber and intake
- Names no prescriber; a questionnaire, with no live visit mentioned
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Semaglutide: no dose printed
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Also lists MOTS-c, BPC-157, Epitalon, TB-500, KPV, Semax, which no pharmacy may lawfully compound
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Same price at every dose
On the GLP-1 tablet and lozenge board Lttl is read on 80% of the rubric's weight: state coverage is left out of its order, not counted against it.
- Rank02
OakPartner
Oak is second on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its stays within legal scope mark; its weakest mark here is dosing guidance.
Oak prices semaglutide only as oral and sublingual among the rows we hold, so there is no other form of it to set beside this one.
- What it prices here
Semaglutide is on Oak's own list with no price we hold.
- Prescriber and intake
- Names its physician network; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: no dose printed
- Follow-up
- Not recorded: our review found no answer on its pages
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Not recorded: no monthly price in this scope
- Price as the dose rises
- Price rises with the dose
On the GLP-1 tablet and lozenge board Oak is read on 65% of the rubric's weight: follow-up, state coverage and price against the market are left out of its order, not counted against it.
- Rank03
Direct MedsPartner
Direct Meds is third on the GLP-1 tablet and lozenge board; its weakest mark here is prescriber and intake.
Direct Meds's own spread between forms: Semaglutide sublingual from $249/mo against injection from $297/mo and Tirzepatide sublingual from $299/mo against injection from $399/mo.
- What it prices here
- Semaglutide sublingual (compounded)from $249/mo
- Tirzepatide sublingual (compounded)from $299/mo
- Prescriber and intake
- Names no prescriber
- Pharmacy named
- Not recorded: our review found no answer on its pages
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Not recorded: our review found no answer on its pages
- Stays within legal scope
- Also lists BPC-157, which no pharmacy may lawfully compound
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Direct Meds is read on 40% of the rubric's weight: pharmacy named, dosing guidance, follow-up, state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank04
MEDGmPartner
MEDGm is fourth on the GLP-1 tablet and lozenge board, carried by its follow-up mark and its state coverage mark; its weakest mark here is prescriber and intake.
MEDGm's own spread between forms: Semaglutide oral from $369/mo against injection from $299/mo.
- What it prices here
- Semaglutide oral (compounded)from $369/mo
- Prescriber and intake
- Names no prescriber
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Semaglutide: no dose printed
- Follow-up
- Ongoing access to a provider included
- Stays within legal scope
- Not recorded: our review found no answer on its pages
- State coverage
- All 50 states
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board MEDGm is read on 70% of the rubric's weight: stays within legal scope and price as the dose rises are left out of its order, not counted against it.
- Rank05
Strut HealthPartner
Strut Health is fifth on the GLP-1 tablet and lozenge board, carried by its stays within legal scope mark and its follow-up mark; its weakest mark here is pharmacy named.
Strut Health's own spread between forms: Semaglutide sublingual from $99/mo against injection from $149/mo and Tirzepatide sublingual from $199/mo against injection from $149/mo.
- What it prices here
- Semaglutide sublingual (compounded)from $99/mo
- Tirzepatide sublingual (compounded)from $199/mo
- Prescriber and intake
- Names one prescribing physician; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Semaglutide: no dose printed; Tirzepatide: no dose printed
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- 49 states
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Strut Health is read on 80% of the rubric's weight: price as the dose rises is left out of its order, not counted against it.
- Rank06
MangoRxPartner
MangoRx is sixth on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its follow-up mark; its weakest mark here is pharmacy named.
MangoRx prices semaglutide only as oral and sublingual among the rows we hold, so there is no other form of it to set beside this one.
- What it prices here
- Semaglutide sublingual (compounded)from $299/mo
- Prescriber and intake
- Names its physician network
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board MangoRx is read on 65% of the rubric's weight: dosing guidance, state coverage and price as the dose rises are left out of its order, not counted against it.
Compare providers 7–18RxSpan MD, Sesame Care, Luvo Health, Willow, MyDrHank, NowPatient, PlexusDx, Try Ageless, Hims, REMEVi, Midi Health, Vyora Wellness
- Rank07
RxSpan MDPartner
RxSpan MD is seventh on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its pharmacy named mark; its weakest mark here is price against the market.
RxSpan MD's own spread between forms: Semaglutide oral from $249/mo against injection from $249/mo and Tirzepatide oral from $349/mo against injection from $329/mo.
- What it prices here
- Semaglutide oral (compounded)from $249/mo
- Tirzepatide oral (compounded)from $349/mo
- Prescriber and intake
- Names its prescribing doctors; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: schedule printed, no strength; Tirzepatide: schedule printed, no strength
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- All 50 states
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board RxSpan MD is read on 80% of the rubric's weight: price as the dose rises is left out of its order, not counted against it.
- Rank08
Sesame CarePartner
Sesame Care is eighth on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its follow-up mark; its weakest mark here is price as the dose rises.
Sesame Care's own spread between forms: Semaglutide oral from $149/mo; $248 a month with the required membership, our total against injection from $349/mo; $448 a month with the required membership, our total.
- What it prices here
- Semaglutide oral (brand)from $149/mo$248 a month with the required membership, our total
- Prescriber and intake
- Names its physician network; a consultation before any prescription
- Pharmacy named
- Not recorded: our review found no answer on its pages
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Not recorded: our review found no answer on its pages
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Price rises with the dose
On the GLP-1 tablet and lozenge board Sesame Care is read on 45% of the rubric's weight: pharmacy named, dosing guidance, stays within legal scope and state coverage are left out of its order, not counted against it.
- Rank09
Luvo HealthPartner
Luvo Health is ninth on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its follow-up mark; its weakest mark here is dosing guidance.
Luvo Health's own spread between forms: Semaglutide oral from $259 per 4 wks; $281 a calendar month, our arithmetic against injection from $209 per 4 wks; $226 a calendar month, our arithmetic.
- What it prices here
- Semaglutide oral (compounded)from $259 per 4 wks$281 a calendar month, our arithmetic
- Prescriber and intake
- Names no prescriber; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: no dose printed
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Same price at every dose
On the GLP-1 tablet and lozenge board Luvo Health is read on 80% of the rubric's weight: state coverage is left out of its order, not counted against it.
- Rank10
WillowPartner
Willow is tenth on the GLP-1 tablet and lozenge board, carried by its stays within legal scope mark and its follow-up mark; its weakest mark here is pharmacy named.
Willow's own spread between forms: Semaglutide sublingual from $299/mo against injection from $299/mo and Tirzepatide sublingual from $399/mo against injection from $399/mo.
- What it prices here
- Semaglutide sublingual (compounded)from $299/mo
- Tirzepatide sublingual (compounded)from $399/mo
- Prescriber and intake
- Names its physician network; a questionnaire, with no live visit mentioned
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Willow is read on 65% of the rubric's weight: dosing guidance, state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank11
MyDrHankPartner
MyDrHank is number 11 on the GLP-1 tablet and lozenge board, carried by its stays within legal scope mark and its follow-up mark; its weakest mark here is pharmacy named.
MyDrHank's own spread between forms: Semaglutide oral from $171/mo against injection from $178/mo.
- What it prices here
- Semaglutide oral (compounded)from $171/mo
- Prescriber and intake
- Names no prescriber; a questionnaire, with no live visit mentioned
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board MyDrHank is read on 65% of the rubric's weight: dosing guidance, state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank12
NowPatient
NowPatient is number 12 on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its pharmacy named mark.
NowPatient's own spread between forms: Semaglutide oral from $99/mo; $119 a month with the required shipping, our total against injection from $215.98/mo; $291 a month with the required shipping, our total.
- What it prices here
- Semaglutide oral (brand)from $99/mo$119 a month with the required shipping, our total
- Prescriber and intake
- A consultation before any prescription
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: strength and schedule printed
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Not recorded: our review found no answer on its pages
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board NowPatient is read on 65% of the rubric's weight: stays within legal scope, state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank13
PlexusDx
PlexusDx is number 13 on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its pharmacy named mark; its weakest mark here is price against the market.
PlexusDx's own spread between forms: Semaglutide oral from $289/mo against injection from $189/mo and Tirzepatide oral from $349/mo against injection from $289/mo.
- What it prices here
- Semaglutide oral (compounded)from $289/mo
- Tirzepatide oral (compounded)from $349/mo
- Prescriber and intake
- Names its prescribing doctors
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: strength and schedule printed; Tirzepatide: strength and schedule printed
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- All 50 states
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board PlexusDx is read on 80% of the rubric's weight: price as the dose rises is left out of its order, not counted against it.
- Rank14
Try Ageless
Try Ageless is number 14 on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its pharmacy named mark.
Try Ageless's own spread between forms: Semaglutide sublingual from $199/mo against injection from $99/mo, Semaglutide oral from $209/mo against injection from $99/mo, Tirzepatide sublingual from $249/mo against injection from $169/mo and Tirzepatide oral from $289/mo against injection from $169/mo.
- What it prices here
- Semaglutide sublingual (compounded)from $199/mo
- Tirzepatide sublingual (compounded)from $249/mo
- Semaglutide oral (compounded)from $209/mo
- Tirzepatide oral (compounded)from $289/mo
- Prescriber and intake
- Names its prescribing doctors; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: strength and schedule printed; Tirzepatide: strength and schedule printed
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Try Ageless is read on 75% of the rubric's weight: state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank15
Hims
Hims is number 15 on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its dosing guidance mark; its weakest mark here is price against the market.
Hims's own spread between forms: Semaglutide oral from $149/mo; $298 a month with the required membership, our total against injection from $199/mo; $348 a month with the required membership, our total.
- What it prices here
- Semaglutide oral (brand)from $149/mo$298 a month with the required membership, our total
- Prescriber and intake
- Names its physician network; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: strength and schedule printed
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Not recorded: our review found no answer on its pages
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Hims is read on 65% of the rubric's weight: stays within legal scope, state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank16
REMEVi
REMEVi is number 16 on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its dosing guidance mark; its weakest mark here is price against the market.
REMEVi's own spread between forms: Semaglutide oral from $249 per 4 wks; $269.75 a calendar month, our calendar-month conversion against injection from $199 per 4 wks; $216 a calendar month, our arithmetic.
- What it prices here
- Semaglutide oral (compounded)from $249 per 4 wks$269.75 a calendar month, our calendar-month conversion
- Prescriber and intake
- Names its physician network; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: strength and schedule printed
- Follow-up
- Ongoing access to a provider included
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- All 50 states
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board REMEVi is read on 80% of the rubric's weight: price as the dose rises is left out of its order, not counted against it.
- Rank17
Midi Health
Midi Health is number 17 on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its dosing guidance mark; its weakest mark here is pharmacy named.
Midi Health's own spread between forms: Semaglutide sublingual from $164 per 4 wks; $178 a calendar month, our arithmetic against injection from $165.90 per 4 wks; $180 a calendar month, our arithmetic and Tirzepatide sublingual from $209 per 4 wks; $226 a calendar month, our arithmetic against injection from $210 per 4 wks; $228 a calendar month, our arithmetic.
- What it prices here
- Semaglutide sublingual (compounded)from $164 per 4 wks$178 a calendar month, our arithmetic
- Tirzepatide sublingual (compounded)from $209 per 4 wks$226 a calendar month, our arithmetic
- Prescriber and intake
- A consultation before any prescription
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Semaglutide: strength and schedule printed; Tirzepatide: strength and schedule printed
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- All 50 states
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Midi Health is read on 80% of the rubric's weight: price as the dose rises is left out of its order, not counted against it.
- Rank18
Vyora Wellness
Vyora Wellness is number 18 on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its stays within legal scope mark; its weakest mark here is price against the market.
Vyora Wellness's own spread between forms: Semaglutide oral from $259/mo against injection from $299/mo and Tirzepatide oral from $359/mo against injection from $399/mo.
- What it prices here
- Semaglutide oral (compounded)from $259/mo
- Tirzepatide oral (compounded)from $359/mo
- Prescriber and intake
- Names its physician network; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Not recorded: our review found no answer on its pages
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Same price at every dose
On the GLP-1 tablet and lozenge board Vyora Wellness is read on 60% of the rubric's weight: dosing guidance, follow-up and state coverage are left out of its order, not counted against it.
Compare providers 19–30Avono Health, VigorMeds, Nu Image Medical, Raeliva, Whoosh Wellness, Heally, Breeze Meds, Rex MD, ZYP Medical, Idgie Health, HealthHub, PrescrYbe
- Rank19
Avono Health
Avono Health is number 19 on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its pharmacy named mark; its weakest mark here is price against the market.
Avono Health's own spread between forms: Semaglutide oral from $299/mo against injection from $269/mo and Tirzepatide oral from $349/mo against injection from $299/mo.
- What it prices here
- Semaglutide oral (compounded)from $299/mo
- Tirzepatide oral (compounded)from $349/mo
- Prescriber and intake
- Names its prescribing doctors; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: schedule printed, no strength; Tirzepatide: schedule printed, no strength
- Follow-up
- Ongoing access to a provider included
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Same price at every dose
On the GLP-1 tablet and lozenge board Avono Health is read on 80% of the rubric's weight: state coverage is left out of its order, not counted against it.
- Rank20
VigorMeds
VigorMeds is number 20 on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its stays within legal scope mark; its weakest mark here is dosing guidance.
VigorMeds's own spread between forms: Semaglutide sublingual from $239/mo against injection from $299/mo and Tirzepatide sublingual from $233/mo against injection from $399/mo.
- What it prices here
- Semaglutide sublingual (compounded)from $239/mo
- Tirzepatide sublingual (compounded)from $233/mo
- Prescriber and intake
- Names its prescribing doctors
- Pharmacy named
- Not recorded: our review found no answer on its pages
- Dosing guidance
- Semaglutide: schedule printed, no strength; Tirzepatide: no dose printed
- Follow-up
- Ongoing access to a provider included
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board VigorMeds is read on 60% of the rubric's weight: pharmacy named, state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank21
Nu Image Medical
Nu Image Medical is number 21 on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its pharmacy named mark; its weakest mark here is price against the market.
Nu Image Medical's own spread between forms: Tirzepatide oral from $314/mo against injection from $289/mo.
- What it prices here
- Semaglutide oral (compounded)from $269/mo
- Tirzepatide oral (compounded)from $314/mo
- Prescriber and intake
- Names its physician network
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: schedule printed, no strength; Tirzepatide: schedule printed, no strength
- Follow-up
- Not recorded: our review found no answer on its pages
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Nu Image Medical is read on 65% of the rubric's weight: follow-up, state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank22
Raeliva
Raeliva is number 22 on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its stays within legal scope mark; its weakest mark here is price against the market.
Raeliva's own spread between forms: Semaglutide sublingual from $260/mo against injection from $219/mo and Tirzepatide sublingual from $359/mo against injection from $299/mo.
- What it prices here
- Semaglutide sublingual (compounded)from $260/mo
- Tirzepatide sublingual (compounded)from $359/mo
- Prescriber and intake
- Names its prescribing doctors; a questionnaire, with no live visit mentioned
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: schedule printed, no strength; Tirzepatide: schedule printed, no strength
- Follow-up
- Ongoing access to a provider included
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Same price at every dose
On the GLP-1 tablet and lozenge board Raeliva is read on 80% of the rubric's weight: state coverage is left out of its order, not counted against it.
- Rank23
Whoosh Wellness
Whoosh Wellness is number 23 on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its follow-up mark.
Whoosh Wellness's own spread between forms: Tirzepatide oral from $249/mo against injection from $249/mo.
- What it prices here
- Tirzepatide oral (compounded)from $249/mo
- Prescriber and intake
- Names one prescribing physician
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Tirzepatide: schedule printed, no strength
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Whoosh Wellness is read on 75% of the rubric's weight: state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank24
Heally
Heally is number 24 on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its follow-up mark; its weakest mark here is pharmacy named.
Heally's own spread between forms: Semaglutide oral from $149/mo against injection from $199/mo.
- What it prices here
- Semaglutide oral (brand)from $149/mo
- Prescriber and intake
- Names its prescribing doctors; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- All 50 states
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Heally is read on 70% of the rubric's weight: dosing guidance and price as the dose rises are left out of its order, not counted against it.
- Rank25
Breeze Meds
Breeze Meds is number 25 on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its stays within legal scope mark; its weakest mark here is dosing guidance.
Breeze Meds's own spread between forms: Semaglutide oral from $299/mo against injection from $199/mo.
- What it prices here
- Semaglutide oral (compounded)from $299/mo
- Tirzepatide oral (compounded)from $399/mo
- Prescriber and intake
- Names its prescribing doctors; a questionnaire, with no live visit mentioned
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: no dose printed; Tirzepatide: no dose printed
- Follow-up
- Not recorded: our review found no answer on its pages
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- All 50 states
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Breeze Meds is read on 70% of the rubric's weight: follow-up and price as the dose rises are left out of its order, not counted against it.
- Rank26
Rex MD
Rex MD is number 26 on the GLP-1 tablet and lozenge board, carried by its dosing guidance mark and its follow-up mark; its weakest mark here is pharmacy named.
Rex MD prices semaglutide only as oral and sublingual among the rows we hold, so there is no other form of it to set beside this one.
- What it prices here
- Semaglutide oral (brand)from $349/mo
- Prescriber and intake
- Names its physician network; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Semaglutide: strength and schedule printed
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- All 50 states
- Price against the market
- Above the market's middle
- Price as the dose rises
- Same price at every dose
- Rank27
ZYP Medical
ZYP Medical is number 27 on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its pharmacy named mark; its weakest mark here is stays within legal scope.
ZYP Medical's own spread between forms: Tirzepatide sublingual from $250/mo against injection from $299 per 4 wks; $324 a calendar month, our arithmetic.
- What it prices here
- Tirzepatide sublingual (compounded)from $250/mo
- Prescriber and intake
- Names one prescribing physician; a consultation before any prescription
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Tirzepatide: strength and schedule printed
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Also lists BPC-157, CJC-1295, Ipamorelin, TB-500, KPV, 5-Amino-1MQ, which no pharmacy may lawfully compound
- State coverage
- 7 states
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Price rises with the dose
- Rank28
Idgie Health
Idgie Health is number 28 on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its stays within legal scope mark; its weakest mark here is prescriber and intake.
Idgie Health's own spread between forms: Semaglutide oral from $287/mo against injection from $134/mo, Semaglutide oral from $287/mo against injection from $149/mo, Tirzepatide oral from $287/mo against injection from $179/mo and Tirzepatide oral from $287/mo against injection from $229/mo.
- What it prices here
- Semaglutide oral (compounded)from $287/mo
- Tirzepatide oral (compounded)from $287/mo
- Prescriber and intake
- Names one prescribing physician; a questionnaire, with no live visit mentioned
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: schedule printed, no strength; Tirzepatide: schedule printed, no strength
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- All 50 states
- Price against the market
- Above the market's middle
- Price as the dose rises
- Price rises with the dose
- Rank29
HealthHub
HealthHub is number 29 on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its stays within legal scope mark; its weakest mark here is prescriber and intake.
HealthHub's own spread between forms: Semaglutide sublingual from $199/mo against injection from $249/mo, Semaglutide oral from $149/mo against injection from $249/mo and Tirzepatide oral from $199/mo against injection from $249/mo.
- What it prices here
- Semaglutide sublingual (compounded)from $199/mo
- Tirzepatide oral (compounded)from $199/mo
- Semaglutide oral (compounded)from $149/mo
- Prescriber and intake
- Names no prescriber; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Ongoing access to a provider included
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board HealthHub is read on 65% of the rubric's weight: dosing guidance, state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank30
PrescrYbe
PrescrYbe is number 30 on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its follow-up mark; its weakest mark here is dosing guidance.
PrescrYbe's own spread between forms: Semaglutide oral from $279 per 4 wks; $302 a calendar month, our arithmetic against injection from $249 per 4 wks; $270 a calendar month, our arithmetic.
- What it prices here
- Semaglutide oral (compounded)from $279 per 4 wks$302 a calendar month, our arithmetic
- Prescriber and intake
- Names its physician network; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: no dose printed
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Not recorded: our review found no answer on its pages
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board PrescrYbe is read on 65% of the rubric's weight: stays within legal scope, state coverage and price as the dose rises are left out of its order, not counted against it.
Compare providers 31–42June Health, ShedRx, HealthSource, Found Youth, Alloy, WePeptideRx, Wisp, Good Girl Rx, Ascend Vitality, AgelessRx, Fitish, He & She MD
- Rank31
June Health
June Health is number 31 on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its dosing guidance mark; its weakest mark here is pharmacy named.
June Health's own spread between forms: Semaglutide oral from $187/mo against injection from $279/mo and Tirzepatide oral from $249/mo against injection from $409/mo.
- What it prices here
- Semaglutide oral (compounded)from $187/mo
- Tirzepatide oral (compounded)from $249/mo
- Prescriber and intake
- Names its physician network
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Semaglutide: strength and schedule printed; Tirzepatide: strength and schedule printed
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Price rises with the dose
On the GLP-1 tablet and lozenge board June Health is read on 80% of the rubric's weight: state coverage is left out of its order, not counted against it.
- Rank32
ShedRx
ShedRx is number 32 on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its stays within legal scope mark; its weakest mark here is pharmacy named.
ShedRx's own spread between forms: Semaglutide oral from $149/mo; $274 a month with the required membership, our total against injection from $199/mo and Semaglutide sublingual from $199/mo against injection from $199/mo.
- What it prices here
- Semaglutide oral (brand)from $149/mo$274 a month with the required membership, our total
- Semaglutide sublingual (compounded)from $199/mo
- Prescriber and intake
- Names its prescribing doctors; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board ShedRx is read on 65% of the rubric's weight: dosing guidance, state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank33
HealthSource
HealthSource is number 33 on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its stays within legal scope mark; its weakest mark here is pharmacy named.
HealthSource's own spread between forms: Tirzepatide sublingual from $399 per 4 wks; $432 a calendar month, our arithmetic against injection from $299 per 4 wks; $324 a calendar month, our arithmetic.
- What it prices here
- Tirzepatide sublingual (compounded)from $399 per 4 wks$432 a calendar month, our arithmetic
- Prescriber and intake
- Names its physician network; a consultation before any prescription
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Tirzepatide: schedule printed, no strength
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- All 50 states
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board HealthSource is read on 80% of the rubric's weight: price as the dose rises is left out of its order, not counted against it.
- Rank34
Found Youth
Found Youth is number 34 on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its follow-up mark.
Found Youth's own spread between forms: Semaglutide sublingual from $229/mo against injection from $249/mo and Tirzepatide sublingual from $249/mo against injection from $329/mo.
- What it prices here
- Semaglutide sublingual (compounded)from $229/mo
- Tirzepatide sublingual (compounded)from $249/mo
- Prescriber and intake
- Names its physician network; a questionnaire, with no live visit mentioned
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: schedule printed, no strength; Tirzepatide: schedule printed, no strength
- Follow-up
- Ongoing access to a provider included
- Stays within legal scope
- Also lists Oxytocin, which no pharmacy may lawfully compound
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Found Youth is read on 75% of the rubric's weight: state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank35
Alloy
Alloy is number 35 on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its follow-up mark; its weakest mark here is prescriber and intake.
Alloy's own spread between forms: Semaglutide oral from $149/mo; $248 a month with the required membership, our total against injection from $70/mo; $169 a month with the required membership, our total and Semaglutide oral from $149/mo; $248 a month with the required membership, our total against injection from $199/mo; $448 a month with the required membership, our total.
- What it prices here
- Semaglutide oral (brand)from $149/mo$248 a month with the required membership, our total
- Prescriber and intake
- Names one prescribing physician; a questionnaire, with no live visit mentioned
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: schedule printed, no strength
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Not recorded: our review found no answer on its pages
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Alloy is read on 65% of the rubric's weight: stays within legal scope, state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank36
WePeptideRx
WePeptideRx is number 36 on the GLP-1 tablet and lozenge board, carried by its dosing guidance mark and its stays within legal scope mark; its weakest mark here is pharmacy named.
WePeptideRx's own spread between forms: Semaglutide oral from $159/mo against injection from $149/mo and Semaglutide oral from $159/mo against injection from $359/mo.
- What it prices here
- Semaglutide oral (compounded)from $159/mo
- Prescriber and intake
- Names one prescribing physician; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Semaglutide: strength and schedule printed
- Follow-up
- Ongoing access to a provider included
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board WePeptideRx is read on 75% of the rubric's weight: state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank37
Wisp
Wisp is number 37 on the GLP-1 tablet and lozenge board, carried by its dosing guidance mark and its stays within legal scope mark; its weakest mark here is pharmacy named.
Wisp prices semaglutide only as oral and sublingual among the rows we hold, so there is no other form of it to set beside this one.
- What it prices here
- Semaglutide sublingual (compounded)from $225/mo
- Prescriber and intake
- A questionnaire, with a live visit available or required in some states
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Semaglutide: strength and schedule printed
- Follow-up
- Not recorded: our review found no answer on its pages
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Wisp is read on 65% of the rubric's weight: follow-up, state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank38
Good Girl Rx
Good Girl Rx is number 38 on the GLP-1 tablet and lozenge board, carried by its stays within legal scope mark and its follow-up mark; its weakest mark here is pharmacy named.
Good Girl Rx's own spread between forms: Semaglutide oral from $300/mo against injection from $179/mo, Semaglutide oral from $297/mo against injection from $179/mo and Tirzepatide oral from $397/mo against injection from $329/mo.
- What it prices here
- Semaglutide oral (compounded)from $300/mo
- Tirzepatide oral (compounded)from $397/mo
- Semaglutide oral (brand)from $297/mo
- Prescriber and intake
- Names its physician network; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Good Girl Rx is read on 65% of the rubric's weight: dosing guidance, state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank39
Ascend Vitality
Ascend Vitality is number 39 on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its follow-up mark; its weakest mark here is stays within legal scope.
Ascend Vitality's own spread between forms: Semaglutide oral from $199/mo against injection from $199/mo.
- What it prices here
- Semaglutide oral (compounded)from $199/mo
- Prescriber and intake
- Names its physician network; a questionnaire, with no live visit mentioned
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Semaglutide: schedule printed, no strength
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Also lists BPC-157, CJC-1295, Ipamorelin, which no pharmacy may lawfully compound
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Ascend Vitality is read on 75% of the rubric's weight: state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank40
AgelessRx
AgelessRx is number 40 on the GLP-1 tablet and lozenge board, carried by its prescriber and intake mark and its follow-up mark; its weakest mark here is pharmacy named.
AgelessRx prices semaglutide only as oral and sublingual among the rows we hold, so there is no other form of it to set beside this one.
- What it prices here
- Semaglutide oral (brand)from $349/mo
- Prescriber and intake
- Names its prescribing doctors; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Semaglutide: no dose printed
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board AgelessRx is read on 75% of the rubric's weight: state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank41
Fitish
Fitish is number 41 on the GLP-1 tablet and lozenge board, carried by its stays within legal scope mark and its follow-up mark; its weakest mark here is pharmacy named.
Fitish's own spread between forms: Tirzepatide sublingual from $339 per 4 wks; $367 a calendar month, our arithmetic against injection from $339/mo.
- What it prices here
- Tirzepatide sublingual (compounded)from $339 per 4 wks$367 a calendar month, our arithmetic
- Prescriber and intake
- Names its physician network; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Tirzepatide: schedule printed, no strength
- Follow-up
- Ongoing access to a provider included
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- All 50 states
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Fitish is read on 80% of the rubric's weight: price as the dose rises is left out of its order, not counted against it.
- Rank42
He & She MD
He & She MD is number 42 on the GLP-1 tablet and lozenge board, carried by its pharmacy named mark and its follow-up mark; its weakest mark here is prescriber and intake.
He & She MD's own spread between forms: Semaglutide oral from $279/mo against injection from $199/mo and Tirzepatide oral from $339/mo against injection from $299/mo.
- What it prices here
- Semaglutide oral (compounded)from $279/mo
- Tirzepatide oral (compounded)from $339/mo
- Prescriber and intake
- Names no prescriber; a questionnaire, with no live visit mentioned
- Pharmacy named
- Names its compounding pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Ongoing access to a provider included
- Stays within legal scope
- Also lists MOTS-c, which no pharmacy may lawfully compound
- State coverage
- All 50 states
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board He & She MD is read on 70% of the rubric's weight: dosing guidance and price as the dose rises are left out of its order, not counted against it.
Compare providers 43–50Nova, AskRx, TelePeptide, Iron Med RX, YourHealthRx, Rewinding RX, ElitePhysiqMD, Loop Health
- Rank43
Nova
Nova is number 43 on the GLP-1 tablet and lozenge board, carried by its follow-up mark and its state coverage mark; its weakest mark here is pharmacy named.
Nova's own spread between forms: Semaglutide sublingual from $169/mo against injection from $229/mo and Tirzepatide sublingual from $174/mo against injection from $279/mo.
- What it prices here
- Semaglutide sublingual (compounded)from $169/mo
- Tirzepatide sublingual (compounded)from $174/mo
- Prescriber and intake
- Not recorded: our review found no answer on its pages
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Also lists Oxytocin, which no pharmacy may lawfully compound
- State coverage
- 49 states
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Price rises with the dose
On the GLP-1 tablet and lozenge board Nova is read on 50% of the rubric's weight: prescriber and intake and dosing guidance are left out of its order, not counted against it.
- Rank44
AskRx
AskRx is number 44 on the GLP-1 tablet and lozenge board, carried by its dosing guidance mark and its follow-up mark; its weakest mark here is pharmacy named.
AskRx's own spread between forms: Semaglutide oral from $149/mo; $249 a month with the required consult, our total against injection from $199/mo; $299 a month with the required consult, our total.
- What it prices here
- Semaglutide oral (brand)from $149/mo$249 a month with the required consult, our total
- Prescriber and intake
- Names no prescriber; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Semaglutide: strength and schedule printed
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Not recorded: our review found no answer on its pages
- State coverage
- All 50 states
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board AskRx is read on 70% of the rubric's weight: stays within legal scope and price as the dose rises are left out of its order, not counted against it.
- Rank45
TelePeptide
TelePeptide is number 45 on the GLP-1 tablet and lozenge board, carried by its stays within legal scope mark and its follow-up mark; its weakest mark here is pharmacy named.
TelePeptide's own spread between forms: Semaglutide sublingual from $229/mo against injection from $199/mo and Tirzepatide oral from $249/mo against injection from $249/mo.
- What it prices here
- Semaglutide sublingual (compounded)from $229/mo
- Tirzepatide oral (compounded)from $249/mo
- Prescriber and intake
- Names no prescriber; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Ongoing access to a provider included
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Same price at every dose
On the GLP-1 tablet and lozenge board TelePeptide is read on 70% of the rubric's weight: dosing guidance and state coverage are left out of its order, not counted against it.
- Rank46
Iron Med RX
Iron Med RX is number 46 on the GLP-1 tablet and lozenge board, carried by its follow-up mark and its stays within legal scope mark; its weakest mark here is pharmacy named.
Iron Med RX's own spread between forms: Semaglutide oral from $196/mo against injection from $149/mo and Tirzepatide oral from $249/mo against injection from $149/mo.
- What it prices here
- Semaglutide oral (compounded)from $196/mo
- Tirzepatide oral (compounded)from $249/mo
- Prescriber and intake
- Names no prescriber; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Semaglutide: no dose printed; Tirzepatide: no dose printed
- Follow-up
- Scheduled check-ins, with messaging
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Iron Med RX is read on 75% of the rubric's weight: state coverage and price as the dose rises are left out of its order, not counted against it.
- Rank47
YourHealthRx
YourHealthRx is number 47 on the GLP-1 tablet and lozenge board, carried by its stays within legal scope mark and its follow-up mark; its weakest mark here is prescriber and intake.
YourHealthRx's own spread between forms: Semaglutide oral from $200/mo against injection from $170/mo and Tirzepatide oral from $220/mo against injection from $210/mo.
- What it prices here
- Semaglutide oral (compounded)from $200/mo
- Tirzepatide oral (compounded)from $220/mo
- Prescriber and intake
- Names no prescriber
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Semaglutide: no dose printed; Tirzepatide: no dose printed
- Follow-up
- Ongoing access to a provider included
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- All 50 states
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Same price at every dose
- Rank48
Rewinding RX
Rewinding RX is number 48 on the GLP-1 tablet and lozenge board, carried by its follow-up mark and its state coverage mark; its weakest mark here is stays within legal scope.
Rewinding RX's own spread between forms: Semaglutide sublingual from $139/mo against injection from $139/mo and Tirzepatide sublingual from $169/mo against injection from $189/mo.
- What it prices here
- Semaglutide sublingual (compounded)from $139/mo
- Tirzepatide sublingual (compounded)from $169/mo
- Prescriber and intake
- Names no prescriber; a questionnaire, with no live visit mentioned
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Unlimited follow-ups, free
- Stays within legal scope
- Also lists MOTS-c, BPC-157, TB-500, which no pharmacy may lawfully compound
- State coverage
- All 50 states
- Price against the market
- At or below the market's middle
- Price as the dose rises
- Same price at every dose
On the GLP-1 tablet and lozenge board Rewinding RX is read on 75% of the rubric's weight: dosing guidance is left out of its order, not counted against it.
- Rank49
ElitePhysiqMD
ElitePhysiqMD is number 49 on the GLP-1 tablet and lozenge board; its weakest mark here is stays within legal scope.
ElitePhysiqMD's own spread between forms: Semaglutide sublingual from $238.50/mo; $327.50 a month with the required membership, our total against injection from $179.10/mo; $268.10 a month with the required membership, our total.
- What it prices here
- Semaglutide sublingual (compounded)from $238.50/mo$327.50 a month with the required membership, our total
- Prescriber and intake
- Names one prescribing physician; a questionnaire, with a live visit available or required in some states
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Not recorded: our review found no answer on its pages
- Stays within legal scope
- Also lists MOTS-c, BPC-157, Kisspeptin, CJC-1295, Ipamorelin, Epitalon, DSIP, TB-500, Semax, Selank, which no pharmacy may lawfully compound
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Price rises with the dose
On the GLP-1 tablet and lozenge board ElitePhysiqMD is read on 60% of the rubric's weight: dosing guidance, follow-up and state coverage are left out of its order, not counted against it.
- Rank50
Loop Health
Loop Health is number 50 on the GLP-1 tablet and lozenge board, carried by its stays within legal scope mark; its weakest mark here is prescriber and intake.
Loop Health's own spread between forms: Semaglutide oral from $199/mo against injection from $199/mo and Tirzepatide oral from $399/mo against injection from $299/mo.
- What it prices here
- Semaglutide oral (compounded)from $199/mo
- Tirzepatide oral (compounded)from $399/mo
- Prescriber and intake
- Names no prescriber
- Pharmacy named
- Does not name its pharmacy
- Dosing guidance
- Not recorded: our review found no answer on its pages
- Follow-up
- Not recorded: our review found no answer on its pages
- Stays within legal scope
- Lists no research-only peptide
- State coverage
- Not recorded: our review found no answer on its pages
- Price against the market
- Above the market's middle
- Price as the dose rises
- Not recorded: not established from its pages
On the GLP-1 tablet and lozenge board Loop Health is read on 55% of the rubric's weight: dosing guidance, follow-up, state coverage and price as the dose rises are left out of its order, not counted against it.
What the order on this board weighs
On the GLP-1 tablet and lozenge board 8 of the rubric's 9 marks apply, rescaled to share the whole order between them: prescriber and intake carries 29%, pharmacy named carries 18% and dosing guidance carries 12%. What each mark reads
- 29%
- Prescriber and intake
- 18%
- Pharmacy named
- 12%
- Dosing guidance
- 12%
- Follow-up
- 12%
- Stays within legal scope
- 6%
- State coverage
- 6%
- Price against the market
- 6%
- Price as the dose rises
Whether a seller pays us is not one of the 8 marks on the GLP-1 tablet and lozenge board, and the rubric cannot read it.
Best GLP-1 tablets and lozenges, ranked on care
Frequently asked questions
- How is the GLP-1 tablet and lozenge board ordered?
- The 11 partners sort first and are labeled; after that the rubric decides. The rubric reads each seller on semaglutide and tirzepatide as a oral and a sublingual, and here prescriber and intake carries 29%, pharmacy named carries 18% and dosing guidance carries 12%.
- Do you earn a commission from the sellers on the GLP-1 tablet and lozenge board?
- On part of it. 11 sellers are partners on the GLP-1 tablet and lozenge board, labeled Partner where they appear; the rest of the links pay us nothing.
- Which marks are not recorded on the GLP-1 tablet and lozenge board?
- Not recorded: state coverage for Lttl, follow-up, state coverage and price against the market for Oak, pharmacy named, dosing guidance, follow-up, state coverage and price as the dose rises for Direct Meds, stays within legal scope and price as the dose rises for MEDGm, price as the dose rises for Strut Health, dosing guidance, state coverage and price as the dose rises for MangoRx, price as the dose rises for RxSpan MD, pharmacy named, dosing guidance, stays within legal scope and state coverage for Sesame Care, state coverage for Luvo Health, dosing guidance, state coverage and price as the dose rises for Willow, dosing guidance, state coverage and price as the dose rises for MyDrHank, stays within legal scope, state coverage and price as the dose rises for NowPatient, price as the dose rises for PlexusDx, state coverage and price as the dose rises for Try Ageless, stays within legal scope, state coverage and price as the dose rises for Hims, price as the dose rises for REMEVi, price as the dose rises for Midi Health, dosing guidance, follow-up and state coverage for Vyora Wellness, state coverage for Avono Health, pharmacy named, state coverage and price as the dose rises for VigorMeds, follow-up, state coverage and price as the dose rises for Nu Image Medical, state coverage for Raeliva, state coverage and price as the dose rises for Whoosh Wellness, dosing guidance and price as the dose rises for Heally, follow-up and price as the dose rises for Breeze Meds, dosing guidance, state coverage and price as the dose rises for HealthHub, stays within legal scope, state coverage and price as the dose rises for PrescrYbe, state coverage for June Health, dosing guidance, state coverage and price as the dose rises for ShedRx, price as the dose rises for HealthSource, state coverage and price as the dose rises for Found Youth, stays within legal scope, state coverage and price as the dose rises for Alloy, state coverage and price as the dose rises for WePeptideRx, follow-up, state coverage and price as the dose rises for Wisp, dosing guidance, state coverage and price as the dose rises for Good Girl Rx, state coverage and price as the dose rises for Ascend Vitality, state coverage and price as the dose rises for AgelessRx, price as the dose rises for Fitish, dosing guidance and price as the dose rises for He & She MD, prescriber and intake and dosing guidance for Nova, stays within legal scope and price as the dose rises for AskRx, dosing guidance and state coverage for TelePeptide, state coverage and price as the dose rises for Iron Med RX, dosing guidance for Rewinding RX, dosing guidance, follow-up and state coverage for ElitePhysiqMD and dosing guidance, follow-up, state coverage and price as the dose rises for Loop Health. Each is left out of that seller's order on this board, because our review of its pages found no answer, and the seller's other marks carry its place instead.
- Which sellers of semaglutide and tirzepatide are not on this board?
- 46 more sellers on our roster publish a price for semaglutide and tirzepatide as a oral and a sublingual and are not ranked on the GLP-1 tablet and lozenge board until we publish a review of each one.